Cyanobiphenyls: Novel H


Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
09 2021
Historique:
received: 09 03 2021
revised: 23 06 2021
accepted: 24 06 2021
pubmed: 5 7 2021
medline: 15 12 2021
entrez: 4 7 2021
Statut: ppublish

Résumé

Alzheimer's disease (AD) is a complex and incurable illness that requires the urgent approval of new effective drugs. However, since 2003, no new molecules have shown successful results in clinical trials, thereby making the common "one compound - one target" paradigm questionable. Recently, the multitarget-directed ligand (MTDL) approach has gained popularity, as compounds targeting at least two biological targets may be potentially more effective in treating AD. On the basis of these findings, we designed, synthesized, and evaluated through biological assays a series of derivatives of alicyclic amines linked by an alkoxy bridge to an aromatic lipophilic moiety of [1,1'-biphenyl]-4-carbonitrile. The research results revealed promising biological activity of the obtained compounds toward the chosen targets involved in AD pathophysiology; the compounds showed high affinity (mostly low nanomolar range of K

Identifiants

pubmed: 34217977
pii: S0045-2068(21)00506-X
doi: 10.1016/j.bioorg.2021.105129
pii:
doi:

Substances chimiques

Biphenyl Compounds 0
Cholinesterase Inhibitors 0
Ligands 0
Monoamine Oxidase Inhibitors 0
Receptors, Histamine H3 0
Monoamine Oxidase EC 1.4.3.4
Acetylcholinesterase EC 3.1.1.7
Butyrylcholinesterase EC 3.1.1.8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105129

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Justyna Godyń (J)

Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Paula Zaręba (P)

Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Dorota Łażewska (D)

Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Dorota Stary (D)

Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

David Reiner-Link (D)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Duesseldorf, Universitaetsstr. 1, Duesseldorf 40225, Germany.

Annika Frank (A)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Duesseldorf, Universitaetsstr. 1, Duesseldorf 40225, Germany.

Gniewomir Latacz (G)

Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Szczepan Mogilski (S)

Department of Pharmacodynamics, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.

Maria Kaleta (M)

Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Agata Doroz-Płonka (A)

Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Annamaria Lubelska (A)

Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Ewelina Honkisz-Orzechowska (E)

Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Agnieszka Olejarz-Maciej (A)

Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Jadwiga Handzlik (J)

Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Holger Stark (H)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Duesseldorf, Universitaetsstr. 1, Duesseldorf 40225, Germany.

Katarzyna Kieć-Kononowicz (K)

Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Barbara Malawska (B)

Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland.

Marek Bajda (M)

Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Medyczna 9, Krakow 30-688, Poland. Electronic address: marek.bajda@uj.edu.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH